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AbstrAct
Hereditary angioedema resulting from the 
deficiency of the C1 inhibitor (HAE-C1-INH) 
is a rare, but potentially life-threatening 
disorder characterized by paroxysmal episodes 
of subcutaneous or submucosal edema. Early 
diagnosis is essential. Management is aimed at 
the prompt elimination of full-fledged attacks, as 
well as at the prevention of edematous episodes. 
The most straightforward means for therapy 
is supplementation with the deficient C1-INH 
protein. Placebo-controlled and open clinical 
studies have established that nanofiltered, 
human C1-INH concentrate, Cinryze® 
(ViroPharma Inc., Exton, PA, USA) (C1-INHCi), 
administered in 1,000 U doses is an effective and 
safe remedy for edematous episodes of HAE-C1-
INH, regardless of the localization of the attack. 
Clinical manifestations rapidly improve and 
then resolve completely following treatment 
with this medicinal product. Additionally, 
C1-INHCi is also appropriate for pre-procedural 
or for routine prophylaxis. The administration 
of 1,000 U C1-INHCi before the (dental, surgical, 
or interventional diagnostic) procedure reduced 
the incidence of edematous episodes compared 
with placebo, and this reduction proved 
significant during routine prophylaxis with 
the administration of this dose every 3–4 days. 
Relapses did not occur, and repeated dosing had 
no influence on the efficacy of the preparation. 
Patients also tolerated treatment with C1-INHCi 
well. The safety of this preparation was 
confirmed by the absence of viral transmission as 
well as by the lack of antibody formation against 
C1-INH during treatment. Nowadays, C1-INHCi 
for intravenous use is the only medicinal 
product indicated both for the prevention and 
management of edematous attacks.
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INtrODUctION
Hereditary angioedema due to C1-inhibitor 
deficiency (HAE-C1-INH) is a rare, autosomal-
dominant, potentially life-threatening disorder 
with a clinical picture characterized by recurrent, 
nonpruritic, self-limiting edema formation in 
the subcutaneous and/or submucosal tissues [1].
Mutation of the gene of the C1-INH protein 
may lead to two different types of the disease. 
In type I HAE, low levels of C1-INH protein can 
be due to intracellular degradation or lack of 
secretion from the cells synthesizing the protein, 
as well as defective transcription. In type II HAE, 
a nonfunctional inhibitor protein is transcribed; 
the serum level of which is normal or even 
appears elevated. The two types of HAE are 
phenotypically indistinguishable in the manner 
of clinical presentation [2, 3]. New mutations 
can also occur, as observed in approximately 
15–25% of cases [4, 5].
The concentrate of human-plasma derived 
C1-INH, the protein missing in patients, has 
been in use for the management of HAE, and 
particularly for the acute therapy of edematous 
attacks, for decades. Recently, multicenter, 
randomized clinical trials have demonstrated, 
for the first time, the effectiveness and safety 
of C1-INH concentrate, also in the prevention 
of these attacks. The studies evaluated the 
nanofiltered human C1-INHCi concentrate 
(Cinryze®, ViroPharma Inc., Exton, PA, USA). The 
following is a concise overview of HAE, the results 
of the clinical trials conducted with C1-INHCi, 
and the application fields for this preparation.
MEtHODs
The authors have briefly reviewed the 
pathomechanism, clinical manifestations, and 
diagnostics of HAE in light of relevant current 
knowledge, by relying on important, pertinent 
publications. As regards to the complex 
management of HAE, the authors examined the 
options of drug therapy, both in emergencies and 
in prevention, in observance of international 
guidelines. Next, the authors summarized the 
information pertaining to C1-INHCi, which may 
be of use to physicians and nurses prescribing 
and administering the product, as well as to 
patients wishing to learn a little more about 
their treatment. The section on C1-INHCi focuses 
on reports of clinical trials, conference abstracts, 
the documents published on the Viropharma 
website, and data available from web pages of 
the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA).
HErEDItArY ANGIOEDEMA tYPE I 
AND tYPE II
Pathomechanism
C1-INH is a serine protease inhibitor (serpin) 
that inactivates several different proteases: C1r, 
C1s, and mannose-binding-lectin-associated 
serine proteases in the complement system; 
factor XII and kallikrein in the contact system; 
factor XI and thrombin in the coagulation 
system; and tissue plasminogen activator and 
plasmin in the fibrinolytic system. C1-INH 
deficiency may result in activation of these four 
closely interrelated cascade systems, potentially 
leading to the release of bradykinin, resulting in 
edema formation [6, 7].
Clinical Symptoms
Time of onset, frequency, duration, and severity 
of individual attacks varies. In approximately 
50% of cases, clinical manifestations may appear 
as early as during childhood. Establishing the 
diagnosis early, preferably before onset of 
clinical symptoms, is essential in cases with a 
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positive family history. The time course of the 
swelling episode typically worsens over 24 hours 
and gradually self-limits over the next 2–3 days. 
Subcutaneous edema is not accompanied 
by pruritus or urticaria [1]. Cutaneous 
manifestations usually regress spontaneously 
over several days. Edema involving the 
submucosa of the upper airways can cause 
airways obstruction and, therefore, may rapidly 
lead to suffocation [1, 8, 9].
Edema localized to the gastrointestinal 
mucosa may mimic clinical manifestations of the 
“acute abdomen” (including colicky abdominal 
pain, vomiting, watery post-attack diarrhea), 
which often lead to unnecessary surgery 
during the abdominal edematous attack [10]. 
In a proportion of patients, exploration reveals 
the etiological role of certain factors in the 
evolution of edematous episodes. The most 
common triggering factors include mechanical 
trauma, surgical procedures performed in the 
head and neck region, mental stress, hormonal 
effects (menstruation, pregnancy), drug effects
(e.g., of estrogen-containing oral contraceptives, 
angiotensin converting enzyme inhibitors), and 
certain infections [11, 12].
Diagnostics
HAE-C1-INH can be diagnosed by exploring 
the patient’s family history, as well as by 
evaluating clinical symptoms and laboratory 
signs. The occurrence of edematous symptoms 
on additional family members may aid in 
establishing the diagnosis. Types I and II HAE 
may be diagnosed by performing complement 
studies. The disorder can be diagnosed in 
this manner when a family history is absent 
(Table 1) [13].
Although genetic testing is not necessary 
in most patients, it may aid in the diagnosis 
of cases where biochemical measurements are 
inconclusive. However, the mutation responsible 
for C1-INH deficiency is only identified in 
90–92% of patients with HAE-C1-INH [5].
Complex Management
The management of patients with HAE requires 
a complex therapeutic approach that consists 
of the therapy and prevention of manifest 
edematous attacks [13–15].
Management of Edematous Attacks
All attacks, irrespective of their location, are 
eligible for treatment as soon as they are clearly 
recognized by the patient [14]. The medicinal 
products appropriate for the treatment of 
edematous attacks differ according to their 
mechanisms of action (Fig. 1), processes of 
manufacture, or methods of dosage.
Deficient or dysfunctional C1-INH can be 
substituted by administering human plasma-
derived C1-INH concentrate. Currently, three 
products of this type are available commercially: 
Cinryze® (ViroPharma Inc.) (C1-INHCi), Cetor®
(Sanquin, Amsterdam, The Netherlands), 
and Berinert® (CSL Behring, Marburg,
Germany) [16–18]. An alternate replacement 
for the deficient protein is recombinant human 
C1-INH concentrate, Rhucin® (Pharming NV, 
Leiden, The Netherlands) [19]. A novel 
Table 1  The changes of complement parameters in types I 
and II of HAE
      Anti-C1-INH 
  C1-INHa C1-INHf C1 C4 antibodies
Type I 
HAE
 ↓ ↓ N ↓ None
Type II 
HAE  
↑/N ↓ N ↓ None
a antigenic level, C1-INH C1 inhibitor, f functional 
activity, N normal value, ↓ reduced value, ↑ elevated value, 
HAE hereditary angioedema
Page 4 of 17 Biol Ther (2012)
therapeutic option is ecallantide (Kalbitor®, 
Dyax, Cambridge, MA, USA), an inhibitor of 
human kallikrein produced by the yeast, Pichia 
pastoris [20]. The action of bradykinin, released 
during the edematous episode, can be blocked 
by administering the bradykinin B2 receptor 
antagonist, icatibant (Firazyr®, Shire, Jersey, JE, 
USA) [21].
If none of the aforementioned drugs 
are available, fresh frozen plasma may be 
administered to relieve severe attacks of 
patients in a critical condition. Antifibrinolytics, 
however, may be considered for add-on 
treatment only [12, 22]. Conventionally used 
glucocorticosteroids and antihistamines are 
ineffective in bradykinin-mediated edema. 
Epinephrine may be administered as add-on 
therapy in upper airways involvement [23].
Prophylaxis
The initial step of prophylaxis should be the 
elimination of the aforementioned triggering 
factors. The second step is the introduction of 
pharmacotherapy. The goal of prophylactic 
treatment is either to decrease the number 
and severity of angioedema attacks (long-
term prophylaxis) or to reduce the likelihood 
of swelling in a patient undergoing a stress or 
procedure likely to precipitate an attack (short-
term prophylaxis) [14, 24].
Introducing long-term prophylaxis becomes 
necessary if: the attacks recur frequently and in 
a severe form; the patient fails to benefit from 
on-demand therapy; HAE leads to significant 
anxiety and poor quality of life; or the patient 
has limited access to emergency medical 
care [13–15, 25].
C1-INHCi has been approved for routine 
prophylaxis. Its mechanism of action is known; 
increasing the plasma levels of C1-INH activity, 
and suppressing contact system activation; thus, 
preventing the generation of bradykinin. The 
properties of C1-INHCi will be detailed later.
Additionally, antifibrinolytics (epsilon-
aminocaproic acid, tranexamic acid) and 
attenuated androgens (danazol, stanozolol, 
oxandrolone) may be administered for 
prophylaxis. Antifibrinolytics are used primarily 
in women and in pediatric patients. Their safety 


















Fig. 1  Target sites of the C1-INH concentrate, kallikrein inhibitor, and bradykinin receptor B2 inhibitor sites during the 
activation of the contact system. C1-INH C1 inhibitor, HMW high molecular weight 
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Nevertheless, their use may be associated with 
hypotension, cardiac arrhythmias, as well as 
rhabdomyolysis or thromboembolism, and their 
prophylactic efficacy is adequate only in a small 
proportion of patients [26].
Nowadays, a 17-alpha-alkylated anabolic 
androgen steroid, known as danazol, is the most 
commonly used prophylactic drug; however, the 
exact mode of action has not yet been elucidated. 
In some patients, a variety of undesirable 
effects should be expected during treatment 
with 17-alpha-alkylated anabolic androgen 
steroid, which are highly dose-dependent, 
such as weight gain, acne, virilization, altered 
libido, menstrual irregularities, headaches, 
depression, fatigue, pro-atherogenic changes in 
lipid profile [27], hepatotoxicity, elevated liver 
enzyme activity, cholestatic jaundice, peliosis 
hepatis, and various neoplastic lesions [28–30].
Short-term prophylaxis is recommended 
for patients undergoing surgical or diagnostic 
procedures undertaken in the head and neck 
region, or for those to undergo an operation 
performed in general anesthesia with 
endotracheal intubation.
The most appropriate strategy is to administer 
C1-INH concentrate 1 hour before surgery, or as 
close to the procedure as is feasible, but less than 
6 hours before the intervention. Alternatively, 
attenuated androgens used for long-term 
prophylaxis may be administered in higher 
doses before surgery and for 4–5 days thereafter, 
to prevent an acute episode [13, 31, 32].
C1-INHCi
The C1-INH protein derived from human 
plasma is highly purified and equivalent to the 
endogenous C1-INH. C1-INHCi is a sterile, stable, 
lyophilized preparation of the C1-INH, prepared 
by Sanquin in the Netherlands with the use of 
plasma obtained from healthy blood donors.
Its manufacturing process combines 
various methods for purification, such 
as  cryoprecipitat ion,  anion-exchange 
chromatography, polyethylene glycol 
precipitation 4,000, pasteurization (heat 
treatment at 60°C for 10 hours in solution with 
stabilizers), and nanofiltration through two 
sequential 15 nm filters. The use of these three 
viral inactivation steps effectively reduces the 
load of enveloped and nonenveloped viruses (the 
overall virus reducing capacities are > 8.7 and 
> 19.1 log10, respectively), and prions (reduction 
of prion load is estimated > 9 log10). The purity 
is ≥ 90% human C1-INH. One unit of C1-INHCi
corresponds to the mean quantity of C1-INH 
present in 1 mL of normal fresh plasma [33, 34].
Pharmacodynamics
In clinical studies, the intravenous (i.v.) 
administration of C1-INHCi demonstrated an 
increase in plasma levels of the C1-INH within 
approximately 1 hour or less of administration.
Both antigenic and functional levels of 
C1-INH increased significantly in patients 
treated with C1-INH, but not in the placebo 
group [16]. The mean increases in functional 
C1-INH activity from before to after treatment 
were generally similar for varying numbers of 
attacks. The C4 values after treatment did not 
change significantly compared with preinjection 
values [35].
Pharmacokinetics
A randomized, parallel-group, open-label 
pharmacokinetics study of C1-INHCi was 
performed in patients with nonsymptomatic 
HAE-C1-INH. The patients received either a single 
dose of 1,000 U, or 1,000 U followed by a second 
1,000 U 60 minutes later. The maximum plasma 
concentration (Cmax) of functional C1-INH and 
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the area under the plasma concentration–time 
curve (AUC) increased from the single to the 
repeated dose, although the increase was not 
dose proportional. Cmax was 0.68 ± 0.08 (n = 12) 
versus 0.33 ± 0.20 (n = 12), and AUC was 
74.5 ± 30.3 (n = 12) versus 95.9 ± 19.6 (n = 13), 
respectively. The mean half-life of C1-INHCi
was 56 hours (range: 11–108 hours) for a single 
dose and 62 hours (range: 16–152 hours) for the 
repeated dose [36, 37].
Acute- and repeated-dose toxicity studies 
were performed in Sprague–Dawley rats, with 
i.v. administration of C1-INHCi at dose levels of 
1, 7, and 28 times the normal dose. No signs of 
toxicity were observed in the single dose study. 
In vitro and in vivo thrombogenicity studies 
showed a potential for clot formation when 
C1-INHCi was administered in doses 14 times 
higher than the recommended clinical dose (over 
200 U/kg). It is not known whether C1-INHCi
passes into the milk. Drug interaction studies 
have not been conducted with C1-INHCi [34, 36].
No animal studies have been completed to 
evaluate the effects of C1-INHCi on carcinogenesis, 
mutagenesis, and impairment of fertility.
Clinical Trials With C1-INHCi
Four phase 3 clinical studies (two placebo-
controlled, two open-label extension) have been 
performed to date.
A Double-Blind, Placebo-Controlled, Clinical 
Study to Investigate the Efficacy and Safety 
of Purified Nanofiltered C1-INH (Human) for 
the Treatment of Hereditary Angioedema in 
Acute Attacks
In this study, the median time to onset of 
unequivocal relief from an attack was 2.41 hours 
in subjects treated with C1-INH concentrate, 
but longer than 4 hours in those given placebo 
(P = 0.02) [16].
A Double-Blind, Placebo-Controlled, Clinical 
Study to Investigate the Efficacy and Safety 
of Purified Nanofiltered C1-INH (Human) as 
Prophylactic Treatment to Prevent Hereditary 
Angioedema Attacks
In this crossover study, the number of attacks per 
12-week period was 6.26 with the administration 
of 1,000 U C1-INHCi every 3–4 days given as 
prophylaxis, compared with 12.73 with placebo 
(P < 0.001). Subjects who received the C1-INH 
concentrate also had significant reductions in 
both severity and duration of attacks, open-
label rescue therapy, and total days with swelling 
compared with placebo [16].
Open-Label Safety/Efficacy Repeat Exposure 
Study of Nanofiltered C1-INH (Human) in the 
Treatment of Acute Hereditary Angioedema 
Attacks
Subjects were treated for a total of 609 acute 
HAE attacks (n = 101; median: three attacks 
per subject; range: 1–57). Within 4 hours after 
C1-INHCi dosing, 87% of attacks achieved 
unequivocal relief of the defining symptom. 
For 95% of attacks, clinical relief was observed 
and/or subjects were discharged home within 
4 hours. For subjects with > 1 attack, the 
proportion of attacks responding within 4 hours 
after C1-INHCi dosing and the time to response 
was comparable regardless of the number of 
attacks treated. Among 84 separate laryngeal 
HAE attacks, none required intubation following 
treatment with C1-INHCi [38].
Open-Label Use of Nanofiltered C1INH 
(Human) for the Prophylactic Treatment to 
Prevent Hereditary Angioedema Attacks
A total of 146 subjects received C1-INHCi as 
HAE prophylaxis for periods ranging from 
8 days to approximately 32 months (median: 
8 months). Before enrollment, subjects reported 
a median monthly HAE attack rate of 3.0
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(range: 0.08–28.00). During therapy with 
prophylactic C1-INHCi, this rate was 0.21 (range: 
0–4.56), and 86% of subjects experienced an 
average of ≤ 1 attack per month. For subjects 
receiving C1-INHCi prophylaxis for at least 
1 year, the monthly attack rate per subject 
remained consistently low (0.34 attacks per 
month) relative to pre-study rates [39].
The authors summarized the objectives, 
design, and primary and secondary endpoints, 
as well as the key findings of these studies in 
Table 2 [16, 37, 39].
Tolerability and Safety
C1-INHCi has been proven to be well tolerated 
and safe, with an adverse event profile indifferent 
to that of placebo. The most common adverse 
reactions are listed in Table 3. Hypersensitivity 
reactions, viral transmission of hepatitis B and C 
virus, and HIV, or the development of clinically 
relevant anti-C1-INH antibodies related to 
C1-INHCi did not occur [16, 35, 38].
The data accumulated in clinical studies have 
been subjected to detailed analyses according 
to various considerations. Reviewing these 
might be of importance for clinical practice 
and, accordingly, a brief summary of additional 
subset analyses follows.
The safety and efficacy of C1-INHCi in attacks 
of diverse localizations are presented below.
Laryngeal Attacks
Eighty-five subjects (74 adults, 11 children) 
received C1-INHCi for 267 laryngeal attacks. 
Only a single subject required intubation after 
treatment with C1-INHCi. The median time 
to the onset of relief during the first treated 
laryngeal attacks was 60 minutes, comparable 
with the overall median response time for 
attacks, at all anatomic locations (45 minutes). 
The efficacy of C1-INHCi for the treatment of 
HAE in subjects with more than one laryngeal 
attack did not diminish with subsequent, 
repeated administrations [35].
Gastrointestinal Attack
Gastrointestinal attacks represented 59%
(351 of 598) of the HAE attacks recorded in 
this study. Seventy-seven subjects experienced
351 gastrointestinal attacks, with 97%
(339 of 351) achieving relief within 4 hours 
after C1-INHCi administration. The median time 
to onset of relief was 30 minutes. The efficacy 
of C1-INHCi did not diminish with subsequent, 
repeated administrations [40].
Subcutaneous Attacks
Subcutaneous attacks on the extremities (n = 86) 
and face (n = 70) represented the second largest 
proportion (156 of 598, 26%) of HAE attacks in 
this study. Fifty-one subjects experienced a total 
of 156 cutaneous attacks, with 96% (149 of 156) 
achieving relief within 4 hours after C1-INHCi 
administration. The median time to onset of 
relief was 30 minutes. The efficacy of C1-INHCi 
did not diminish with subsequent, repeated 
administrations [41].
The Safety and Efficacy of C1-INHCi in 
Various Patient Populations
Pediatric Patients
The management of acute episodes
Overall, this open-label, multicenter study 
evaluated subjects aged ≥ 1 year, with a diagnosis 
of HAE; this subset analysis presents data on 
patients aged < 18 years. Twenty-two pediatric 
subjects [aged 2–5 years old (n = 1), 6–11 years old 
(n = 9), and 12–17 years old (n = 12)] experienced 
121 HAE attacks in total, with 89% (108 of 121) 
achieving relief within 4 hours of C1-INHCi 
administration. A 2-year-old subject was given 
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two 500 U doses for a facial attack, and reported 
symptom relief within 3 hours. Gastrointestinal 
attacks were the most common manifestations 
of HAE. Of the 64 gastrointestinal attacks seen 
in 6–11-year-old and in 12–17-year-old subjects, 
97% (35 of 36) and 89% (25 of 28), respectively, 
relief ensued within 4 hours. No subjects with a 
laryngeal attack required intubation [42].
Prophylaxis
This subset analysis from the open-label 
extension study evaluated the use of C1-INHCi 
for routine prophylaxis in pediatric subjects < 18 
years of age with HAE. Before enrollment, the
23 children (aged 2–5 years old [n = 2], 6–11 
years old [n = 9], and 12–17 years old [n = 12])
in this study reported a mean HAE attack rate of 
4.4 ± 5.7 per month. C1-INHCi therapy reduced 
HAE attacks to ≤ 1 per month in the majority 
of the pediatric subjects. The only treatment-
emergent AEs considered drug-related were 
headache, nausea, and infusion-site erythema; 
none of which were severe [43].
Pregnant Women
Unlike placebo-controlled trials, pregnancy was 
not an exclusion criterion in two open-label 
studies investigating the use of C1-INHCi for the 
treatment of acute attacks and for prophylaxis 
of HAE attacks. In these studies, women were 
successfully treated with C1-INHCi during 
pregnancy.
Fourteen pregnant women were treated 
with C1-INHCi in the studies; one subject 
who was treated in both studies delivered 
a healthy neonate. Of the 13 remaining 
subjects, three subjects enrolled in the acute 
treatment study. One patient received eight 
doses and two subjects received a single dose 
of C1-INHCi at delivery only. All three subjects 
delivered healthy neonates. Ten subjects
in the prophylaxis study received a median
of 34 doses (range: 2–85) during their pregnancy 
and reported the following outcomes: seven 
subjects delivered eight healthy neonates
(one set of twins), one subject (45 years old) 
with a history of miscarriage and ectopic 
pregnancy had a spontaneous abortion 
(reported as possible ectopic pregnancy), and 
one subject delivered a stillborn neonate with 
multiple congenital anomalies. This subject 
was first exposed to C1-INHCi in the second 
trimester. One subject had an unknown 
outcome [44].
Table 3  Adverse reactions reported with C1-INHCi in clinical studies
System organ class Frequency: adverse drug reaction
 Common Uncommon
Metabolism and nutrition disorders – Hyperglycemia
Nervous system disorders – Dizziness, headache
Vascular disorders – Venous thrombosis, phlebitis, venous burning, 
  hot flush
Respiratory, thoracic and mediastinal disorders – Cough
Gastrointestinal disorders – Nausea, vomiting, diarrhea, abdominal pain
Skin and subcutaneous tissue disorders Rash Contact dermatitis, erythema, pruritus
Musculoskeletal and connective tissue disorders – Joint swelling, arthralgia, myalgia
General disorders and administration site conditions – Injection site rash/erythema, infusion site pain, 
  chest discomfort, pyrexia
C1-INHC1 Cinryze 
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Pre-procedure Administration of C1-INHCi
C1-INHCi 1,000 U i.v. was administered within 
24 hours before elective medical, dental, or 
surgical procedures that may trigger HAE. 
Forty-one patients (eight children, 33 adults) 
received C1-INHCi before 91 procedures (40 in 
children, 51 in adults). Approximately 56% of 
the procedures were dental, and 44% involved 
surgery or diagnostic intervention. A single 
1,000 U dose was administered before 96% of 
the procedures; two separate 1,000 U doses 
were used before two coronary artery bypass 
surgeries, one gastrointestinal endoscopy, 
and during labor/delivery of one pregnancy.
HAE attacks did not occur after 72 hours 
of C1-INHCi administration in 98% of the 
procedures. A genitourinary attack occurring 
after a dental procedure, and a laryngeal attack 
seen after laparoscopy, were reported within 72 
hours after the administration of C1-INHCi. Both 
resolved after treatment with an additional dose 
of C1-INHCi [45].
Site of Care Analysis on Administration of 
C1-INHCi
In June 2010, and before implementation of an 
infusion training program, 516 patients were 
on commercial C1-INHCi and were analyzed 
regarding their site of care status (note: 
11 patients had no data). Of these 516 patients, 
243 patients administered C1-INHCi at home. 
A total of 42% reported self-administration 
(overall, self-administration was chosen by 
20% of patients). In 16% of patients, the drug 
was administered by a family member, and in 
23%, by a home healthcare worker. A total of 
120 patients received treatment at an infusion 
center, and 142 in the physician’s office. The 
age of the study population ranged from 
5 to 84 years. Thus, home infusion and self-
administration is a viable option for patients 
with HAE [46, 47].
There are programs in place that offer 
convenience and support to patients with HAE. 
An infusion training program in the United 
States and European Union is a benefit designed 
to develop the skills of patients or caregivers in 
reconstitution and administration technique, 
as well as to provide a resource to patients 
and caregivers after initial training has been 
completed. Other programs include the home 
delivery of medications. In the United States, 
there is a program designed to offer assistance 
with insurance coverage and financial support 
for insurance claims and co-payments.
Approved Indications
United States
C1-INHCi is the first and only C1-INH approved 
by the FDA for the routine prophylaxis of 
HAE attacks in adults and adolescent patients 
(12 years of age and older) with hereditary 
C1-INH deficiency. It also gained approval for 
self-administration in May 2009 [37, 48].
Europe
The European Union approved C1-INHCi in 2011 
for the treatment and pre-procedure prevention 
of angioedema attacks in adults and adolescents 
with HAE. Additionally, it is indicated for the 
routine prevention of severe and recurrent 
HAE attacks in adults and adolescents. In 
addition, the EMA granted approval for self-
administration and the medicine is available on 
medical prescription only [36].
Administration and Dosage
C1-INHCi is for i.v. use only. The freeze-dried 
C1-INHCi powder should be stored between 
2 and 25°C. Patients should not attempt to self-
administer unless trained appropriately by a 
clinician.
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A dose of 1,000 U C1-INHCi can be 
administered every 3–4 days for routine 
prophylaxis to prevent angioedema attacks 
in patients with HAE. For pre-procedure 
prophylaxis before medical, dental, or surgical 
interventions, 1,000 U C1-INHCi is given within 
24 hours before the procedure.
For the acute treatment of HAE attacks, 
1,000 U should be administered at the first sign 
of an attack. Regardless of the patient’s body 
weight, a second dose of 1,000 U may be given 
if the patient has not responded adequately after 
1 hour, or sooner for severe attacks, or if the start 
of treatment had been delayed.
Treatment with C1-INHCi is contraindicated 
if the patient has known, life-threatening 
hypersensitivity (e.g., anaphylaxis) to 
C1-INH (human), or to any ingredient of the 
preparation [37].
cONcLUsION
The management of HAE-C1-INH has 
changed significantly during recent years. 
Therapeutic options have increased, and new 
medicinal products have been introduced. 
The latter provide the means for developing 
individualized treatment strategies on one 
hand, as well as widen patient access to 
therapy on the other. C1-INHCi is approved 
for long-term prophylaxis both in Europe, 
and in the United States. Clinical studies 
have clearly confirmed the efficacy and safety 
of this drug in HAE attacks (regardless of the 
localization of edema), during pre-procedure 
prophylaxis before elective medical, dental, 
or surgical interventions, or for long-term 
prophylaxis. C1-INHCi was quick and efficient 
in relieving clinical manifestations. Relapses 
did not occur and repeated administration 
did not reduce therapeutic efficacy. Neither 
viral transmission nor the development of 
anti-C1-INH antibodies has been observed.
Pre-procedure prophylaxis proved effective for 
the prevention of edematous attacks. Long-
term prophylaxis reduced the number, severity, 
and duration of edematous episodes. Although 
i.v. drug delivery is relatively problem-free and 
feasible, subcutaneous administration would 
be more convenient and more suitable for 
self-administration.
The clinical evaluation of the newly developed 
C1-INHCi formulation for subcutaneous dosing 
is currently in phase 2 studies. The dose 
appropriate for long-term prophylaxis may be 
individually adjusted, determining the lowest 
effective dose and dosing frequency best suited 
for the given patient. It must be stressed that no 
treatment modality exists for preventing attacks 
with certainty and, hence, severe upper airways 
edema can occur despite the therapy being 
administered. In such a case, emergency therapy 
should be introduced promptly, especially 
in airways edema. In addition to using state-
of-the art therapeutic modalities, the regular 
monitoring and uninterrupted education of 
patients, establishing the means for home-based 
treatment, and defense of the patients’ interests 
are all integral elements of efficient, complex 
management.
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